Double Bond Pharmaceutical International AB (publ), a pharmaceutical company, engages in the development and commercialization of approaches for the treatment of oncological, infectious, autoimmune, and other life-threatening diseases. It offers Temodex, a therapy to treat malignant brain tumors; and SA033, a therapy to treat cancers in liver. The company is also developing Belopenem for the treatment of bacterial pneumonia. Double Bond Pharmaceutical International AB (publ) was founded in 2014 and is based in Uppsala, Sweden.